Cencora Gestion

Gestion contrôle des critères 3/4

Le PDG Cencora est Bob Mauch, nommé en Oct2022, a un mandat de 2.08 ans. La rémunération annuelle totale est $ 7.70M, composée du salaire de 12.7% et des bonus 87.3%, y compris les actions et options de la société. détient directement 0.012% des actions de la société, d'une valeur de $ 6.06M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 2.5 ans et 9.5 ans.

Informations clés

Bob Mauch

Directeur général

US$7.7m

Rémunération totale

Pourcentage du salaire du PDG	12.7%
Durée du mandat du directeur général	2.1yrs
Propriété du PDG	0.01%
Durée moyenne d'occupation des postes de direction	2.5yrs
Durée moyenne du mandat des membres du conseil d'administration	9.5yrs

Mises à jour récentes de la gestion

Recent updates

Cencora: Credentials To Die For, But Underlying Issues Make Case For 'Hold' Rating

Sep 18

Market Participants Recognise Cencora, Inc.'s (NYSE:COR) Earnings

Jul 16

Cencora: Potential Exists, But Ambiguous Valuations And Data Breach Risks Are Concerning

Jun 30

Are Investors Undervaluing Cencora, Inc. (NYSE:COR) By 43%?

Jun 28

Here's Why Cencora (NYSE:COR) Can Manage Its Debt Responsibly

Jun 09

Do Cencora's (NYSE:COR) Earnings Warrant Your Attention?

May 21

Investors Interested In Cencora, Inc.'s (NYSE:COR) Earnings

Apr 05

Cencora Remains Chronically Undervalued, With Material Growth Potential

Mar 25

Cencora, Inc.'s (NYSE:COR) Intrinsic Value Is Potentially 53% Above Its Share Price

Mar 18

Cencora (NYSE:COR) Seems To Use Debt Quite Sensibly

Feb 25

Cencora (NYSE:COR) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Feb 07

Cencora, Inc.'s (NYSE:COR) Business Is Yet to Catch Up With Its Share Price

Jan 05

Cencora: Continued Economic Value On The Table Across All Investment Horizons

Jan 04

A Look At The Fair Value Of Cencora, Inc. (NYSE:COR)

Dec 15

Cencora (NYSE:COR) Is Paying Out A Larger Dividend Than Last Year

Nov 05

Is Cencora (NYSE:COR) A Risky Investment?

Nov 03

Cencora: New Name, Same Old Economic Leverage, Reiterate Buy

Oct 18

AmerisourceBergen Corporation (NYSE:ABC) Shares Could Be 34% Below Their Intrinsic Value Estimate

Aug 01

AmerisourceBergen: Great Company, Wrong Price (Rating Downgrade)

Jul 28

We Think AmerisourceBergen (NYSE:ABC) Can Stay On Top Of Its Debt

Jun 19

Is AmerisourceBergen Corporation (NYSE:ABC) Trading At A 28% Discount?

May 01

Here's Why We Think AmerisourceBergen (NYSE:ABC) Is Well Worth Watching

Apr 10

Analyse de la rémunération des PDG

Comment la rémunération de Bob Mauch a-t-elle évolué par rapport aux bénéfices de Cencora?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	US$2b
Jun 30 2024	n/a	n/a	US$2b
Mar 31 2024	n/a	n/a	US$2b
Dec 31 2023	n/a	n/a	US$2b
Sep 30 2023	US$8m	US$975k	US$2b
Jun 30 2023	n/a	n/a	US$2b
Mar 31 2023	n/a	n/a	US$2b
Dec 31 2022	n/a	n/a	US$2b
Sep 30 2022	US$6m	US$850k	US$2b
Jun 30 2022	n/a	n/a	US$2b
Mar 31 2022	n/a	n/a	US$2b
Dec 31 2021	n/a	n/a	US$2b
Sep 30 2021	US$6m	US$800k	US$2b
Jun 30 2021	n/a	n/a	-US$4b
Mar 31 2021	n/a	n/a	-US$4b
Dec 31 2020	n/a	n/a	-US$3b
Sep 30 2020	US$4m	US$700k	-US$3b
Jun 30 2020	n/a	n/a	US$2b
Mar 31 2020	n/a	n/a	US$2b
Dec 31 2019	n/a	n/a	US$649m
Sep 30 2019	US$4m	US$675k	US$855m
Jun 30 2019	n/a	n/a	US$956m
Mar 31 2019	n/a	n/a	US$930m
Dec 31 2018	n/a	n/a	US$1b
Sep 30 2018	US$3m	US$675k	US$2b

Rémunération vs marché: La rémunération totale de Bob ($USD 7.70M ) est inférieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 12.73M ).

Rémunération et revenus: La rémunération de Bob a augmenté de plus de 20 % tandis que les bénéfices de l'entreprise ont chuté de plus de 20 % au cours de l'année écoulée.

PDG

Bob Mauch (57 yo)

2.1yrs

Titularisation

US$7,697,850

Compensation

Dr. Robert P. Mauch, PharmD, Ph D., also known as Bob, is an Executive Vice President at Cencora, Inc. (formerly known as AmerisourceBergen Corporation) since February 2015 and served as its Group Presiden...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Steven Collis	Executive Chairman	13.5yrs	US$17.51m	0.15% $ 70.8m
Robert Mauch	President	2.1yrs	US$7.70m	0.012% $ 6.1m
James Cleary	Executive VP & CFO	6yrs	US$5.45m	0.058% $ 28.3m
Elizabeth Campbell	Executive VP & Chief Legal Officer	3.2yrs	US$4.03m	0.0042% $ 2.1m
Lazarus Krikorian	Senior VP	12.8yrs	pas de données	0.010% $ 5.0m
Pawan Verma	Executive VP	less than a year	pas de données	pas de données
Bennett Murphy	Senior Vice President of Investor Relations	no data	pas de données	pas de données
Jennifer Dubas	Senior VP & Chief Compliance Officer	no data	pas de données	pas de données
Silvana Battaglia	Executive VP & Chief Human Resources Officer	5.8yrs	US$3.48m	0.0056% $ 2.7m
Richard Tremonte	EVP & President of U.S. Pharmaceuticals	less than a year	pas de données	pas de données
Ann Anaya	Senior VP and Chief Diversity Equity & Inclusion Officer	2.8yrs	pas de données	pas de données
Juan Guerra	EVP & President of International Business Group	less than a year	pas de données	pas de données

2.5yrs

Durée moyenne de l'emploi

57yo

Âge moyen

Gestion expérimentée: L'équipe de direction de COR est considérée comme expérimentée (ancienneté moyenne 2.5 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Steven Collis	Executive Chairman	13.5yrs	US$17.51m	0.15% $ 70.8m
Robert Mauch	President	less than a year	US$7.70m	0.012% $ 6.1m
Lauren Tyler	Independent Director	1.1yrs	pas de données	pas de données
Richard Gochnauer	Independent Director	16.2yrs	US$300.10k	0.011% $ 5.6m
Mark M. Durcan	Lead Independent Director	9.2yrs	US$380.05k	0.010% $ 4.9m
Lon Greenberg	Independent Director	11.5yrs	US$332.60k	0.0057% $ 2.8m
Kathleen Hyle	Independent Director	14.5yrs	US$320.10k	0.011% $ 5.2m
Dennis Nally	Independent Director	4.8yrs	US$375.36k	0.0052% $ 2.5m
Ornella Barra	Director	9.8yrs	pas de données	pas de données
Henry McGee	Independent Director	20yrs	US$320.10k	0.0077% $ 3.7m
Lorence Kim	Independent director	2.1yrs	US$397.33k	0.000090% $ 43.8k
Redonda Miller	Independent Director	1.8yrs	US$311.82k	0.00080% $ 389.5k

9.5yrs

Durée moyenne de l'emploi

64yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de COR sont considérés comme expérimentés (ancienneté moyenne 9.5 ans).

Cencora Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

Cencora, Inc. Announces Management Appointments

Executive Chairman notifies of intention to sell stock

Chairman notifies of intention to sell stock

Chairman notifies of intention to sell stock

Cencora, Inc. Elects Frank Clyburn as New Independent Director, Effective October 1, 2024

Chairman notifies of intention to sell stock

Recent updates

Cencora (NYSE:COR) Is Increasing Its Dividend To $0.55

Fourth quarter dividend increased to US$0.55

Full year 2024 earnings: EPS misses analyst expectations

Cencora, Inc. Declares Quarterly Dividend, Payable on November 29, 2024

Cencora, Inc. (NYSE:COR) entered into a definitive agreement to acquire 85% stake in Retina Consultants of America from Webster Capital IV, L.P., fund managed by Webster Equity Partners, L.P. for $5.1 billion.

Cencora, Inc. Announces Management Appointments

Why We're Not Concerned About Cencora, Inc.'s (NYSE:COR) Share Price

Executive Chairman notifies of intention to sell stock

Here's Why We Think Cencora (NYSE:COR) Is Well Worth Watching

Cencora, Inc. to Report Q4, 2024 Results on Nov 06, 2024

Chairman notifies of intention to sell stock

Here's Why Cencora (NYSE:COR) Can Manage Its Debt Responsibly

Cencora: Credentials To Die For, But Underlying Issues Make Case For 'Hold' Rating

Chairman notifies of intention to sell stock

Cencora, Inc. Elects Frank Clyburn as New Independent Director, Effective October 1, 2024

Third quarter dividend of US$0.51 announced

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Cencora, Inc. Declares Quarterly Cash Dividend, Payable on August 26, 2024

Chairman notifies of intention to sell stock

Market Participants Recognise Cencora, Inc.'s (NYSE:COR) Earnings

Cencora, Inc. to Report Q3, 2024 Results on Jul 31, 2024

Cencora: Potential Exists, But Ambiguous Valuations And Data Breach Risks Are Concerning

Are Investors Undervaluing Cencora, Inc. (NYSE:COR) By 43%?

Chairman notifies of intention to sell stock

Here's Why Cencora (NYSE:COR) Can Manage Its Debt Responsibly

Insider exercised options and sold US$3.5m worth of stock

Chairman exercised options and sold US$1.4m worth of stock

Do Cencora's (NYSE:COR) Earnings Warrant Your Attention?

Second quarter dividend of US$0.51 announced

Cencora, Inc. Declares Quarterly Cash Dividend on Common Share, Payable on May 24, 2024

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Cencora, Inc. (NYSE:COR) announces an Equity Buyback for $2,000 million worth of its shares.

Executive VP & COO exercised options and sold US$4.9m worth of stock

Cencora, Inc. to Report Q2, 2024 Results on May 01, 2024

Investors Interested In Cencora, Inc.'s (NYSE:COR) Earnings

Cencora Remains Chronically Undervalued, With Material Growth Potential

Chairman exercised options and sold US$1.6m worth of stock

Cencora, Inc.'s (NYSE:COR) Intrinsic Value Is Potentially 53% Above Its Share Price

Cencora, Inc. Reaffirms Guidance for Year 2024

Cencora, Inc. Announces CEO Changes, Effective October 1, 2024

Cencora (NYSE:COR) Seems To Use Debt Quite Sensibly

Cencora’s FormularyDecisions Launches Payer Resource for Cell and Gene Therapy Products

Cencora (NYSE:COR) Is Posting Promising Earnings But The Good News Doesn’t Stop There

First quarter dividend of US$0.51 announced

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Price target increased by 9.0% to US$235

Consensus EPS estimates fall by 14%

Cencora, Inc. Declares Quarterly Cash Dividend on Common Share, Payable on February 26, 2024

Cencora, Inc., Annual General Meeting, Mar 12, 2024

Cencora, Inc., Annual General Meeting, Mar 12, 2024

Cencora, Inc. to Report Q1, 2024 Results on Jan 31, 2024

Cencora, Inc.'s (NYSE:COR) Business Is Yet to Catch Up With Its Share Price

Cencora: Continued Economic Value On The Table Across All Investment Horizons

Chairman recently sold US$8.7m worth of stock

A Look At The Fair Value Of Cencora, Inc. (NYSE:COR)

Chairman exercised options and sold US$3.1m worth of stock

Insider recently sold US$2.0m worth of stock

Executive VP & CFO exercised options and sold US$3.1m worth of stock

Cencora (NYSE:COR) Is Paying Out A Larger Dividend Than Last Year

Cencora, Inc. Declares Quarterly Dividend, Payable November 27, 2023

Is Cencora (NYSE:COR) A Risky Investment?

Full year 2023 earnings: EPS misses analyst expectations

Cencora: New Name, Same Old Economic Leverage, Reiterate Buy

Chairman exercised options and sold US$2.7m worth of stock

Cencora, Inc. to Report Q4, 2023 Results on Nov 02, 2023

Insider exercised options and sold US$2.0m worth of stock

Now 20% undervalued after recent price drop

Chairman exercised options and sold US$1.0m worth of stock

Now 21% undervalued